In conclusion, despite objective limitations of this study such as the retrospective design, the low number of patients and controls in the multiplex cohorts and a low number of patients with SIDP, acute-onset CIDP, PDN, and MMN in the ELISA cohort, we could confirm a previous report on IL8 in CSF as a diagnostic biomarker, specifically in patients with GBS and CIDP. The gene discussed is CXCL8; the disease is Guillain-Barre syndrome.